A service of arranging or bringing about contact between an investment manager and an issuer or potential issuer.
Name Change Reflects Extensive Scientific and Corporate Brand Equity Previously Established under Grace Therapeutics Grace Therapeutics will begin trading on Nasdaq under the trading symbol "GRCE" effective October 28, 2024 Virtual Key Opinion Leader Event to be held...
Data Readout Expected Early Calendar 2025; NDA Submission on Track for 1H Calendar 2025PRINCETON, N.J., Sept. 25, 2024 -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel injectable formulation of...
During this fireside chat, we welcome Acasti Pharma, ticker symbol of ACST on the NASDAQ and their CEO, Prashant Kohli. This Fireside Chat was recorded during the Lytham Partners Spring 2023 Investor Conference.
This panel presentation features executives from three different companies that are looking to advance innovations in healthcare, each of them with ongoing or planned Phase 3 trials here. We've titled the panel, Phase 3 Drugs to Watch. Hosted by Lytham Partners...
Acasti is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Acasti's novel drug delivery technologies have the potential to improve the performance of currently marketed drugs by achieving faster onset of action, enhanced...
This panel features three different companies that are looking to advance innovations in rare diseases or what are often designated by the FDA is orphan drugs. We have a diverse panel of participants that can hopefully each provide their own unique perspective on the...
Acasti is a late-stage specialty pharma company with drug delivery capability and technologies addressing rare and orphan diseases. The Company’s novel drug delivery technologies have the potential to improve the performance of currently marketed drugs by achieving...